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BACKGROUND: Internationally, most atrial fibrillation (AF) management guidelines recommend opportunistic screening for AF in 
people ≥65 years of age and oral anticoagulant treatment for those at high stroke risk (CHA₂DS₂-VA≥2). However, gaps remain 
in screening and treatment.
METHODS AND RESULTS: General practitioners/nurses at practices in rural Australia (n=8) screened eligible patients (≥65 years 
of age without AF) using a smartphone ECG during practice visits. eHealth tools included electronic prompts, guideline-based 
electronic decision support, and regular data reports. Clinical audit tools extracted de-identified data. Results were com-
pared with an earlier study in metropolitan practices (n=8) and nonrandomized control practices (n=69). Cost-effectiveness 
analysis compared population-based screening with no screening and included screening, treatment, and hospitalization 
costs for stroke and serious bleeding events. Patients (n=3103, 34%) were screened (mean age, 75.1±6.8 years; 47% men) 
and 36 (1.2%) new AF cases were confirmed (mean age, 77.0 years; 64% men; mean CHA₂DS₂-VA, 3.2). Oral anticoagulant 
treatment rates for patients with CHA₂DS₂-VA≥2 were 82% (screen detected) versus 74% (preexisting AF)(P=NS), similar to 
metropolitan and nonrandomized control practices. The incremental cost-effectiveness ratio for population-based screen-
ing was AU$16 578 per quality-adjusted life year gained and AU$84 383 per stroke prevented compared with no screening. 
National implementation would prevent 147 strokes per year. Increasing the proportion screened to 75% would prevent 177 
additional strokes per year.
CONCLUSIONS: An AF screening program in rural practices, supported by eHealth tools, screened 34% of eligible patients 
and was cost-effective. Oral anticoagulant treatment rates were relatively high at baseline, trending upward during the study. 
Increasing the proportion screened would prevent many more strokes with minimal incremental cost-effectiveness ratio 
change. eHealth tools, including data reports, may be a valuable addition to future programs.
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Internationally, opportunistic screening for atrial fibril-lation (AF) in people ≥65  years of age is now rec-ommended by most guidelines.1,2 Single timepoint 
screening detects undiagnosed AF, which is often 
asymptomatic, in approximately 1.4% of people in this 
age group.3 Guidelines generally recommend treat-
ment with oral anticoagulants (OACs),1,2 which can re-
duce the risk of AF-related stroke by 64% for those at 
high risk (“sexless” CHA₂DS₂-VA [C = congestive heart 
failure/left ventricular dysfunction, H = high blood pres-
sure, A2 = 75 years of age and older, D = diabetes 
mellitus, S2 = stroke/transient ischemic attack/throm-
boembolism, V = vascular disease (coronary artery dis-
ease, myocardial infarction, peripheral artery disease, 
aortic plaque), A = 65–74 years of age] risk score≥2).4
Large gaps in screening and treatment exist in 
practice. A survey conducted by The Economist in 
2017 reported that only 11% of people ≥65 years of 
age were screened in Australian general practices in 
the previous fortnight.5 Our previous 2018 study using 
eHealth tools conducted in metropolitan general prac-
tices increased screening to 16% of eligible patients.6 
In terms of treatment, rates have historically been 50% 
to 60%. However, since non–vitamin K dependent 
OAC (NOAC) medicines were introduced, an increase 
in treatment rates has been reported in Europe (>77% 
in England7 and >65% in Denmark8). This trend was 
also reflected in our 2018 metropolitan study, which 
reported a treatment rate of 71% for those diagnosed 
with AF before the study, increasing to >80% for those 
diagnosed during the study period.6
Australians living in rural areas have more limited 
access to health services and worse cardiovascular 
outcomes.9 The ratios of general practitioners (GPs), 
specialists, and nurses per capita of population are sig-
nificantly lower in rural areas than in metropolitan areas, 
and access to specialist cardiac care is more limited.10,11 
Approximately 25% of the rural population suffers from 
cardiovascular diseases compared with 20% in metro-
politan areas, and the likelihood of hospitalization and 
death resulting from cardiac events increases with the 
distance from metropolitan areas.12 General practices 
play a key role in supporting cardiac health in rural areas 
as they tend to provide a broader range of community 
services compared with metropolitan practices.13
Several of our previous studies showed that oppor-
tunistic screening in primary care by GPs and nurses 
was feasible.6,14,15 A suite of customized eHealth tools, 
including an automated prompt and electronic de-
cision support (EDS), were found to be promising.6 
These tools have been refined and enhanced with a 
quality improvement (QI) focus16,17 and are designed to 
support all stages of screening.
This study aims to improve the proportion of pa-
tients screened and treated for AF using the refined 
eHealth tools and to inform strategies on AF screen-
ing implementation in the rural setting. In addition, this 
study provides the first cost-effectiveness analysis in 
Australian general practice.
METHODS
This study was conducted in a convenience sample of 
8 rural general practices from September 2018 to July 
CLINICAL PERSPECTIVE
What Is New?
• This study extends the evidence base in rural 
areas by demonstrating that a screening pro-
gram using eHealth tools in a rural general 
practice setting can successfully screen 34% of 
eligible patients with atrial fibrillation with guide-
line-indicated treatment rates >80% for screen-
detected atrial fibrillation cases.
• Economic modeling showed that the program 
was cost-effective compared with no screening.
• Oral anticoagulant treatment rates for eligible 
patients were higher than previous studies at 
baseline (>70%) and were trending upward dur-
ing the study (around 80%).
What Are the Clinical Implications?
• eHealth tools, particularly customized data reports 
as part of an audit and feedback system, may be a 
valuable addition to screening programs.
• Half of the practices screened 40% to 50% of 
eligible patients, suggesting that this may repre-
sent a ceiling of patients captured by opportun-
istic atrial fibrillation screening programs in the 
general practice setting.
• Increasing the proportion screened would pre-
vent many more strokes with minimal change to 
the incremental cost-effectiveness ratio.
Nonstandard Abbreviations and Acronyms
AF atrial fibrillation
EDS electronic decision support
GP general practitioner
iECG handheld single-lead smartphone ECG
ICER incremental cost-effectiveness ratio
NOAC non–vitamin K dependent oral  
anticoagulant
OAC oral anticoagulant
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2019 in rural New South Wales, Australia. Practices 
were required to be located outside a major city 
(generally categorized under the Australian Statistical 
Geography Standard–Remoteness Area 201618 code 
2 “inner regional Australia”) and were recruited by 
advertisements in primary health network newslet-
ters and by word of mouth. Participating practices 
provided written informed consent, and patients pro-
vided oral consent for screening. This study was ap-
proved by the University of Sydney Human Research 
Ethics Committee (Project No. 2017/1017; Clinical 
Trial Registration No. ACTRN12618000004268). The 
data and materials will not be made available to other 
researchers as data sharing is not permitted by our 
ethics committee approval. Researchers interested in 
the data, methods, or analysis can contact the corre-
sponding author for more information.
The methods for this study have been previously de-
scribed in detail.17 Briefly, GPs and/or practice nurses 
offered screening for AF with smartphone handheld 
single-lead ECGs (iECGs) (KardiaMobile) to eligible 
patients attending the practice for any reason. Eligible 
patients were those ≥65 years of age without an exist-
ing AF diagnosis who had not already been screened 
with the iECG within the past 12 months. All follow-up 
for those with abnormal screening results according 
to the iECG app (“possible AF” or “unclassified”) and 
treatment decisions were at the discretion of the GP.
To support screening, practices were provided with 
eHealth tools (Figure 1).
• Screening prompt: An app located in a third-party 
hosting platform automatically extracted information 
from patients’ electronic medical records. Using this 
information in real time, a prompt appeared when 
an eligible patient’s file was opened. The iECG auto-
mated screening result was also recorded in this app.
• EDS: For those diagnosed with AF (either by screen-
ing or otherwise), the EDS app (also located on 
the third-party hosting platform) calculated their 
CHA₂DS₂-VA stroke risk score and made guideline 
recommendations regarding treatment. This app 
was part of the HealthTracker suite of cardiovascular 
QI tools.
• Tailored clinical audit data for QI reporting: 
Customized, de-identified clinical audit data extracts 
were obtained monthly from participating practices. 
These data were used to report back to practices 
and included data on the number and proportion 
screened, the number of patients with new AF, and 
the proportion treated according to guidelines.
Reimbursement
Practices were paid $1000 to cover study setup time 
and data extraction costs plus $10 per patient screened 
(paid per 100 patients to encourage greater numbers). 
This was intended to cover the costs of screening in 
the Australian fee-for-service context and to replicate 
a real-world fee if screening was covered by Medicare. 
Screening was free for patients, although any usual 
consultation fees applied.
Data Collection and Analysis
De-identified data extracts included demographic, 
iECG screening, medication, and diagnostic informa-
tion from the practices’ electronic patient records. The 
data extracts were designed to collect data for all ac-
tive patients of the practices, that is, patients who had 
attended at least 3 times in the past 2 years and once 
in the past 6 months.
To provide additional context about broader 
screening and treatment trends, data from this study 
were compared with 2 other de-identified data sets: 
Figure 1. Screening process and eHealth tools adapted from our 2018 metropolitan study.6
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the metropolitan group and the nonrandomized 
control group. These comparator data sets were 
collected from other Australian studies also using 
the HealthTracker app, with prospectively collected 
data using the same data extraction tool and data 
fields. The metropolitan group was from our 2018 
AF screening study,6 which included 8 metropolitan 
general practices. The nonrandomized control group 
was composed of 69 practices (64 metropolitan and 
5 rural) that were using HealthTracker for general car-
diovascular QI studies that did not involve AF screen-
ing. For the purposes of comparisons of treatment 
rates before and during the study period, the non-
randomized control group data were split into AF di-
agnoses before January 1, 2018 (baseline treatment 
rate) and AF diagnosed on or later than January 1, 
2018 (AF diagnosed during the study period).
Descriptive analyses for the rural practices were 
carried out using Microsoft Excel. Descriptive analy-
ses of nonrandomized control data were performed 
using R Statistical Programming, version 3.6.1.19 
Comparisons of treatment rates between groups 
were calculated using the Fisher exact test (2-sided 
P values) performed using 2×2 contingency tables 
(GraphPad Prism version 7.04) with significance set a 
priori at P<0.05. Although our protocol paper specified 
a chi-square test, the Fisher exact test was used as it 
was more accurate with the small numbers involved.
A detailed process evaluation was carried out using 
mixed methods, including semistructured interviews 
with selected practice staff. This evaluation examined 
outcomes related to implementation success and the 
acceptability/competing demands of the screening 
program. Methods and results of this evaluation have 
been described elsewhere.16
Cost-Effectiveness Analysis
The iECG screening program was evaluated by 
comparing population-based AF screening with 
no screening from an Australian health funder per-
spective. The economic model developed in the 
SEARCH-AF (Screening Education and Recognition 
in Community Pharmacies of Atrial Fibrillation)20 
pharmacy screening study was adapted to evalu-
ate iECG screening in general practice. The model 
has previously been explained in detail.20 Briefly, the 
model compares the cost of iECG screening, diagno-
sis, and treatment in general practice to diagnosed 
AF in the unscreened population of Australian men 
and women 65 to 84 years of age. That is, it com-
pares population-based AF screening to no screen-
ing. It assumes a base rate of AF (both diagnosed 
and unknown) and follows a cohort of the population 
65 to 84 years of age for 10 years with annual stroke 
events and all-cause mortality.
Stroke costs included hospitalization, rehabilitation, 
and other ongoing medical costs. For this study, the 
model was updated to include the cost of an echocar-
diogram for those diagnosed and the costs of major 
bleeding episodes for those on OAC treatment and a 
treatment regimen consistent with current trends (that 
is, including NOACs prescribed at rates observed in 
the current study).
The model included several key assumptions (full 
list included as Table S1).
• The proportion screened was that observed in this 
study.
• The prevalence of diagnosed AF in the population 
≥65 years of age was 4.4%.3
• The prevalence of unknown AF in the population ≥65 
years of age was 1.4%.3
• OAC and antiplatelet treatment rates were as 
observed for all patients diagnosed during the 
study period (both screen detected and otherwise 
detected).
• The iECG test sensitivity was 97%, and specificity 
was 92%.
• The cost per screen was $20.
• For those diagnosed with AF, annual treatment and 
monitoring costs for those on OACs were $1063.78 
(warfarin) and $1401.73 (mean cost for NOACs) and 
included annual costs of medication, pathology, GP, 
and specialist visits.
Costs for hospitalization for stroke were obtained 
from Cadilhac et al21 and were updated to 2019 prices 
using the Australian Health Price Deflator Index. In ad-
dition, a present value of 5.09 quality-adjusted life years 
(QALYs) (gained over a lifetime) was used for each isch-
emic stroke prevented by screening.21
Results are presented in Australian dollars as an 
incremental cost-effectiveness ratio (ICER) per stroke 
avoided and per QALY gained for population-based 
screening compared with no screening. Sensitivity 
analyses were also performed for different proportions 
of patients screened, price reductions in NOAC medi-
cines, differences in iECG test sensitivity and specific-
ity, differences in OAC treatment rates, and differences 
in rates of major bleeding episodes.
Outcomes
Key study outcomes were the following:17
• the proportion of screened patients with confirmed 
new AF,
• the proportion of AF and screened patients where 
the EDS was accessed,
• the proportion of patients with AF diagnosed during 
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(CHA₂DS₂-VA risk score≥2)1 who were prescribed an 
OAC according to guidelines,
• baseline AF prevalence in patients ≥65 years of age 
compared with metropolitan and nonrandomized 
control groups,
• new screen-detected AF incidence at the end of the 
study period in patients ≥65 years of age compared 
with the metropolitan and nonrandomized control 
groups, and 
• rates of OAC and antiplatelet treatment at baseline 
and completion for patients in the OAC recom-
mended category compared with the metropolitan 
and nonrandomized control groups.
RESULTS
Screening, Diagnosis, and Treatment
A total of 8 general practices were recruited and 
screened a total of 3103 eligible patients (mean age, 
75.1±6.8  years; 47% men) during the study period. 
The median screening period was 4.6 months (range, 
1.7–7.5  months). Practices screened a mean of 34% 
(median 35%) of eligible patients (range, 9%–51% per 
practice), with 4 of 8 practices screening >40% of eligi-
ble patients (Figure 2). In general, screening was high-
est in the first 1 to 2 months and declined thereafter. 
The mean proportion of all eligible patients who at-
tended the practices during the study period was 94%.
GPs (n=22) screened 31% (range, 1–182 per GP) of pa-
tients and nurses (n=40) screened 69% (range, 1–192 
per nurse). According to the iECG automated algo-
rithm (as entered into the app by GPs/nurses), 83% of 
screenings were normal, 13% were unclassified, and 
4% were possible AF.
In total, 36 (1.2%) of new cases of screen-detected 
AF were confirmed (mean age, 77.0 years; 64% men; 
mean CHA₂DS₂-VA, 3.2) (Table  1). The proportion of 
screen-detected patients with AF with at least 1 non-
age or sex risk factor was 83%, and the proportion 
in the OAC recommended category (CHA₂DS₂-VA≥2) 
was 94%. Characteristics and CHA₂DS₂-VA groups for 
those with screen-detected AF, otherwise-detected AF 
(during the study period), and AF detected before the 
study are presented in Table 1.
OAC treatment rates of patients with AF with 
CHA₂DS₂-VA≥2 were 82% (screen-detected), 75% 
(otherwise-detected during study period), and 74% 
(preexisting AF), with no significant differences be-
tween treatment rates in the screen-detected group 
and other groups (Table  1). The EDS was accessed 
for 54 of 1337 (4%) patients 65 years of age and older 
with AF and for 4 of 36 (11%) patients with new screen- 
detected AF.
AF Prevalence and Treatment Rates 
Compared With Metropolitan and 
Nonrandomized Control Groups
The baseline prevalence of AF in the rural and metro-
politan practices and nonrandomized control groups 
ranged from 9% to 12% (Table 2).
There were no significant differences between 
the rural and metropolitan practices’ treatment rates 
of those with AF detected before the study or during 
the study (screen-detected and otherwise-detected) 
(Table  2). Likewise, the treatment rates in the rural 
practices were similar to those in the nonrandomized 
control practices at baseline and during the study pe-
riod (Table 2). The OAC treatment rates in all 3 cohorts 
tended to increase from baseline (Table 2), in contrast 
to antiplatelets.
Cost-Effectiveness Analysis
Our cost-effectiveness modeling showed that for 
population-based AF screening for Australian men 
and women 65 to 84 years of age, assuming a 34% 
screening participation rate with a treatment rate of 
82% in the screened population and a test sensitivity of 
97% and specificity of 92%, the ICER per QALY gained 
was AU$16 578 and the ICER per stroke avoided was 
≥≥84 383 compared with no screening.
Increasing the screening participation rate has a 
negligible effect on the ICER, but substantially in-
creases the number of strokes prevented, that is, 
effectiveness (Table 3). Increasing the screening par-
ticipation rate from 34% to 50% raises the number 
of strokes prevented from the base case of 147 per 
year to 216 per year (or 1467 to 2157 over 10 years). 
With a 75% screening participation rate, a total of 
324 strokes are prevented each year (or 3235 strokes 
over 10 years) when compared with the no screening 
scenario.
Raising the OAC treatment rate also prevents more 
strokes, with a relatively small impact on the ICER. An 
OAC treatment rate of 90% (in both the screened and 
unscreened populations) would prevent a total of 1610 
strokes over 10 years, with an ICER per QALY gained 
of $16 188 compared with no screening.
For population-based screening, lowering the 
cost of NOAC treatment decreases the ICER per 
QALY gained to AU$14 997 (12.5% price reduction) or 
AU$13  416 (25% price reduction) compared with no 
screening.
Furthermore, changes to the iECG test sensitivity 
and specificity did not have material impacts on the 
ICER per stroke prevented nor the ICER per QALY 
gained compared with no screening. However, increas-
ing the test sensitivity to 100% did prevent an additional 
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regarding major bleeding rates did not have a material 
impact on the ICER per stroke prevented nor the ICER 
per QALY gained compared with no screening.
DISCUSSION
This study investigated the impact of an AF screening 
program in rural general practices using an iECG together 
with a suite of custom-designed eHealth tools designed 
to increase the proportion screened and treated for AF 
in accordance with guidelines. GPs and nurses at par-
ticipating practices screened a total of 3103 eligible pa-
tients, and 36 (1.2%) new cases of AF were confirmed, 
with 82% prescribed OAC according to guidelines.
This study featured a unique suite of integrated, 
customized eHealth tools to support all stages of AF 
screening and treatment in general practice. These 
Figure 2. Screening flowchart.
*Unclassified results may be attributed to sinus bradycardia, sinus tachycardia, left or right bundle 
branch block, multiple ectopic beats, or other arrythmias. AF indicates atrial fibrillation; CHA₂DS₂-VA, C 
= congestive heart failure/left ventricular dysfunction, H = high blood pressure, A2 = 75 years of age and 
older, D = diabetes mellitus, S2 = stroke/transient ischemic attack/thromboembolism, V = vascular disease 
(coronary artery disease, myocardial infarction, peripheral artery disease, aortic plaque), A = 65 to 74 years 
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tools were refined following our metropolitan study6 
and included an automated screening prompt (with 
improved visibility and reliability), an EDS app to guide 
treatment, and de-identified data extracts and with 
regular QI audit and feedback reporting to practices. 
We are not aware of any other studies that include 
tools to cover all stages of AF screening and treatment, 
including customized feedback. In particular, the re-
fined screening prompt and the improved QI reporting 
were useful and motivating for participating GPs and 
nurses.16
Proportion Screened and Treated
Practices screened 34% of eligible patients who at-
tended during the study period, which is substantially 
higher than the 16% achieved in our metropolitan study.6 
Half of the study practices were able to screen >40% 
of eligible patients, although 51% was the maximum 
reached. It appeared that even practices with broad 
uptake and high motivation across staff were not able 
to capture more than 50% of eligible patients, which 
GPs and nurses indicated was largely attributed to time 
constraints and technical issues (eg, difficulty taking a 




Baseline: AF Diagnosed 
Before Study
(n=36) (n=58) (n=1243)
Age, y, mean±SD 77.0±6.1 77.0±8.4 79.2±7.8
Male, n (%) 23 (64) 32 (55) 662 (53)
Mean CHA₂DS₂-VA 3.2 3.3 3.7
CHA₂DS₂-VA≥2, n (% of total) 34 (94) 55 (95) 1223 (98)
CHA₂DS₂-VA≥2 and prescribed OACs, n (% of those with 
CHA₂DS₂-VA≥2)
28 (82) 41 (75) P=0.444* 908 (74) P=0.326*
≥1 nonage or sex risk factors, n (% of total) 30 (83) 54 (93) 1178 (95)
AF indicates atrial fibrillation; and CHA₂DS₂-VA, C = congestive heart failure/left ventricular dysfunction, H = high blood pressure, A2 = 75 years of age and 
older, D = diabetes mellitus, S2 = stroke/transient ischemic attack/thromboembolism, V = vascular disease (coronary artery disease, myocardial infarction, 
peripheral artery disease, aortic plaque), A = 65 to 74 years of age; and OAC, oral anticoagulant.
*P value for comparison to screen-detected AF.





Nonrandomized Control Practices 
(n=69)
Total active* patients ≥65 years of age 10 896 13 679 30 116
Baseline AF prevalence 12% 11% 9%
Baseline: AF detected before study with CHA2DS₂-VA≥2
Total, n 1223 1306 1875
Prescribed OAC, n (%) 908 (74) 933 (71) P=0.118† 1450 (77) P=0.052†
Prescribed antiplatelet alone, n (%) 178 (15) 213 (16) 248 (13)
Not prescribed OAC or antiplatelet, n (%) 137 (11) 160 (12) 177 (9)
Screen-detected AF during study period with CHA₂DS₂-VA≥2
Total, n 34 18 N/A
Prescribed OAC, n (%) 28 (82) 15 (83) P>0.999† N/A
Prescribed antiplatelet alone, n (%) 1 (3) 1 (6) N/A
Not prescribed OAC or antiplatelet, n (%) 5 (15) 2 (11) N/A
All AF detected during study period (screen detected+otherwise detected) with CHA₂DS₂-VA≥2
Total, n 89 64 399
Prescribed OAC, n (%) 69 (78) 54 (84) P=0.312† 333 (83) P=0.218†
Prescribed antiplatelet alone, n (%) 7 (8) 3 (5) 29 (7)
Not prescribed OAC or antiplatelet, n (%) 13 (15) 7 (11) 37 (9)
AF indicates atrial fibrillation; CHA₂DS₂-VA, C = congestive heart failure/left ventricular dysfunction, H = high blood pressure, A2 = 75 years of age and older, 
D = diabetes mellitus, S2 = stroke/transient ischemic attack/thromboembolism, V = vascular disease (coronary artery disease, myocardial infarction, peripheral 
artery disease, aortic plaque), A = 65 to 74 years of age; and OAC, oral anticoagulant.
*Active patients are those who attended the practice at least 3 times in the past 2 years and once in the past 6 months.
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reading on some patients).16 Key features of the most 
successful practices included leadership from a senior 
GP “screening champion,” clear protocols for follow-
up of abnormal results for nurse-led screening, and 
sufficient staff time allocation for screening. These are 
discussed in detail in our qualitative realist evaluation.16
A recent study of AF screening in 184 Canadian 
practices was able to screen 42% of eligible 
Table 3. Cost-Effectiveness of Population-Based AF Screening Compared With No Screening and Sensitivity Analyses 
Over 10 Years
Base Case
Screening participation rate, % 34 50 60 70 75
Number of strokes prevented 1467 2157 2588 3020 3235
Net cost [ICER] per stroke prevented compared with 
no screening
$84 383 $83 304 $82 922 $82 649 $82 540
Net cost [ICER] per QALY gained compared with no 
screening
$16 578 $16 366 $16 291 $16 238 $16 216
NOAC price reduction - 12.5% 25%
Number of strokes prevented 1467 1467 1467
Net cost [ICER] per stroke prevented compared with 
no screening
$84 383 $76 336 $68 289
Net cost [ICER] per QALY gained compared with no 
screening
$16 578 $14 997 $13 416
iECG test sensitivity 97% 92% 100%
Number of strokes prevented 1467 1391 1512
Net cost [ICER] per stroke prevented compared with 
no screening
$84 383 $85 940 $83 524
Net cost [ICER] per QALY gained compared with no 
screening
$16 578 $16 884 $16 409
iECG test specificity 92% 89% 93%
Number of strokes prevented 1467 1467 1467
Net cost [ICER] per stroke prevented compared with 
no screening
$84 383 $86 818 $83 571
Net cost [ICER] per QALY gained compared with no 
screening
$16 578 $17 057 $16 419
OAC treatment rate 74%*/82%† 55% 90%
Number of strokes prevented 1467 984 1610
Net cost [ICER] per stroke prevented compared with 
no screening
$84 383 $97 731 $82 397
Net cost [ICER] per QALY gained compared with no 
screening
$16 578 $19 201 $16 188
Major bleeds–crude excess incidence rate per 1000 
person-years of major bleeds for those 65–74 years of 
age
4.8 2.2 7.4
Number of strokes prevented 1467 1467 1467
Net cost [ICER] per stroke prevented compared with 
no screening
$84 383 $83 409 $85 358
Net cost [ICER] per QALY gained compared with no 
screening
$16 578 $16 387 $16 770
Major bleeds–crude excess incidence rate per 1000 
person-years of major bleeds for those 75–84 years of 
age
4.2 1.3 7.2
Number of strokes prevented 1467 1467 1467
Net cost [ICER] per stroke prevented compared with 
no screening
$84 383 $83 753 $85 035
Net cost [ICER] per QALY gained compared with no 
screening
$16 578 $16 454 $16 706
AF indicates atrial fibrillation; ICER, incremental cost effectiveness ratio; QALY, quality-adjusted life year; NOAC, non-vitamin K dependent anticoagulant; 
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patients.22 In addition, a study from the Netherlands 
where patients ≥65 years of age were screened in 10 
general practices during influenza vaccination ses-
sions captured 35% of eligible patients, which is al-
most identical to our study.23 These results suggest 
that 40% to 50% may be a “ceiling” of eligible pa-
tients captured by an opportunistic screening pro-
gram in general practice.
As with the metropolitan study, treatment rates 
were high at baseline (>70%) compared with historical 
Australian data and increased during the study. The 
treatment rates were highest for screen-detected AF 
(>80%). These treatment rates and trends were similar 
to those in the nonrandomized control practices. These 
rates are higher than previously reported in Australia, 
which were about 55% to 60%24 before the introduc-
tion of NOACs (preferred by the Australian guidelines).1 
Our results show a similar trend to recent European 
treatment rates of around 65% to 80%8,25,26 since the 
introduction of NOACs.
Our results also show a decline in antiplatelet pre-
scription for those not on OACs. Of the patients di-
agnosed during the study period (≥65  years of age 
with CHA₂DS₂-VA≥2) who were not prescribed OACs 
(n=20), only a minority were prescribed antiplatelets 
alone (n=7) with the remainder on no therapy (n=13). 
Of the 7 patients prescribed antiplatelets alone, 2 of 
these patients were prescribed antiplatelets before 
being diagnosed with AF (1 of whom had cardiovas-
cular disease) and another 3 of these patients also 
had cardiovascular disease, which may be the reason 
antiplatelets were prescribed. This suggests that the 
prescription of antiplatelets alone for AF may be declin-
ing, as was recently reported in a US study27 and that 
effectively the prescribing decision is becoming “OAC 
or no treatment.”
Rural Setting
This study extends the evidence base in rural areas 
and shows that a screening program in the rural gen-
eral practice setting can successfully screen a large 
number of eligible patients with AF with guideline-in-
dicated treatment rates >80% for screen-detected AF 
cases. A screening program using pulse palpation in 
rural general practice in Ireland achieved a similar reach 
to our study (30% of the general practice population 
≥65 years of age screened), although OAC treatment 
rates were lower (65%).28 The authors noted important 
differences regarding the density of population in rural 
studies compared with metropolitan studies, with im-
plications for rural patients’ access to primary and sec-
ondary care.
Prevention programs suitable for rural areas are 
particularly important given that people living in these 
areas tend to have worse cardiovascular outcomes 
and less access to specialist medical services.9 
Rural general practice is potentially an ideal setting 
for implementation of innovative primary care-based 
cardiac programs, such as ours, which contribute to 
upskilling GPs in cardiac care, training nurses to pro-
vide cardiac education/screening, and using novel 
technology.
Cost-Effectiveness
Our cost-effectiveness modeling showed that for 
population-based AF screening in general practice 
for Australian men and women 65 to 84 years of age, 
the ICER per QALY gained was AU$16  578 and the 
ICER per stroke avoided was AU$84 383 compared 
with no screening. Increasing the proportion screened 
from 34% to 75% would prevent an additional 177 
strokes per year (or 1768 strokes over 10 years) with a 
Figure 3. Summary of findings.
AF indicates atrial fibrillation; CHA₂DS₂-VA, C = congestive heart failure/left ventricular dysfunction, H = high blood pressure, A2 = 75 
years of age and older, D = diabetes mellitus, S2 = stroke/transient ischemic attack/thromboembolism, V = vascular disease (coronary 
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negligible effect on the ICER. These figures are higher 
than for SEARCH-AF,20 largely driven by an increased 
uptake of OAC treatment rates and in particular the 
higher prescription rates of NOACs. The increased 
proportion of people treated with OAC reduces the 
ICER, although this is offset by the higher cost of treat-
ment with NOACs. These figures are well within the 
accepted thresholds of Australian government health 
expenditures.29 This is consistent with several other 
studies, which found AF screening to be cost-effec-
tive30 or even cost-saving.31
Importantly, although we were able to screen 34% 
of eligible people with these tools (and have suggested 
that 40%–50% may be a “ceiling” of patients captured 
with opportunistic screening programs), these analy-
ses highlight the impact of increasing the proportion 
screened in terms of stroke prevention and the need 
to consider new approaches to break the 40% to 50% 
barrier.
Limitations
The proportion of non-normal results according to 
the iECG device algorithm was relatively high at 17% 
(possible AF, 4%; unclassified, 13%). This added to 
the workload substantially for practices, as was also 
noted in a recent Canadian study,22 as all of these 
patients require some degree of follow-up. In rela-
tion to the possible AF readings, it is likely that some 
were paroxysmal AF (AF not present on a subse-
quent 12-lead ECG) or false positives (eg, attributed 
to sinus arrhythmia, multiple atrial ectopics, or a poor 
quality trace). It is also possible that some AF diag-
noses were not recorded in the clinical system (see 
Limitations below). In relation to the unclassified re-
sults, previous studies have usually reported lower 
rates closer to 10%.6,14 Improvements in the device 
algorithm (eg to identify sinus tachycardia/bradycar-
dia) and training staff in techniques to take clearer 
readings will reduce this burden. We note that the 
research team was not able to review the iECGs and 
relied on GPs/nurses to manually enter the device’s 
interpretation into the AF app. The iECG automated 
algorithm has been reported to have a sensitivity of 
97% and specificity of 92%.20
The EDS was only used for a low proportion of 
patients. This is probably because it was in a sep-
arate app and was not accessed by GPs as it re-
quired extra clicks. Ideally, an EDS would need to be 
a more integral part of the electronic medical record 
system. Alternatively, an automatic calculation of pa-
tients’ CHA₂DS₂-VA scores in the electronic medical 
record would assist, particularly if it included an alert 
to review treatment when the score changed (espe-
cially when it exceeds a treatment-recommendation 
threshold).
The study relied on de-identified data collected 
from practices. This was routinely collected general 
practice data with all its inherent limitations. For exam-
ple, if GPs recorded a diagnosis of AF in the free-text 
notes section instead of adding it as a condition from 
a drop-down list, this would not be caught in our data, 
meaning our figures may underestimate the true rate of 
AF detected during the study. In addition, these data 
were limited to active patients because of the defini-
tion in the data collection tool. “Active patients” were 
defined as those who had attended the practice at 
least 3 times in the past 2 years and once in the past 
6 months. Therefore, our data may be biased toward 
people with more chronic conditions requiring more 
frequent attendance at the practice.
There were some limitations in relation to the 
cost-effectiveness analysis. A key methodological lim-
itation is that a probabilistic sensitivity analysis was not 
undertaken to show model uncertainty, and therefore 
the model only reports point estimates on cost-effec-
tiveness. However, this is consistent with the main pur-
pose of the model, which was to provide an estimate 
of the cost-effectiveness and number of strokes pre-
vented if the AF-SMART system was implemented na-
tionally. In addition, the model has not been validated 
or calibrated to test whether predicted events are con-
sistent with observed data.
CONCLUSIONS
An AF screening program in rural general practices, 
supported by eHealth tools, screened 34% of eligi-
ble patients, with 82% of new screen-detected cases 
treated according to guideline (Figure  3). Half of the 
practices screened 40% to 50% of eligible patients, 
suggesting that this may represent a “ceiling” of pa-
tients captured by opportunistic AF screening pro-
grams. OAC treatment rates were higher than previous 
studies at baseline and were trending upward during 
the study. Increasing the proportion screened would 
prevent many more strokes with minimal changes to 
the ICER. This may require new methods to break 
through the ceiling captured by numerous opportun-
istic programs. eHealth tools, particularly customized 
data reports as part of an audit and feedback sys-
tem, may be a valuable addition to future screening 
programs.
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Table S1. Cost-effectiveness model assumptions. 
Item Cost/measure Details Source 
Prevalence of known AF in the 
population aged 65-84 years 
4.4%  Lowres et al, 201332  
Prevalence of unknown AF in the 
population aged 65-84 years 
1.4%  Lowres et al, 20193 
iECG test sensitivity 
iECG test specificity 
97% (95% CI: 92-100%) 
92% (95% CI: 89-93%)  
 Lowres et al, 201420  
Population  1,113,661(Male 65-74) 
1,168,074(Female 65-74) 
576,829 (Male 75-84) 
658,438 (Female 75-84) 
June 2019 Australian Bureau of Statistics, 
201933 
OAC treatment rates (unscreened 
population) 
OAC: 74%  




AF-SMART rural results section 
[baseline data] 





 AF-SMART rural results section 
[screen-detected AF during 
study] 
OAC treatment (screened and 
unscreened): warfarin vs NOACs 
Warfarin: 10% 
NOACs: 90%  
Apportioned using a 
mean cost for NOACs 
AF-SMART rural results [not 
published]  
Screening participation rate 34%  AF-SMART rural results section 
Cost per screen $20 Includes cost of eHealth 
tools and GP/nurse time 
(5min)  
Based on the cost of recording 
a 12-lead ECG without 
interpretation (MBS item 
1170234) 
Discount rate 5%   
Follow-up costs for those with abnormal screening result [possible AF or unclassified] 
12 lead ECG $31.75 1 per possible AF result 
 
0.85 per unclassified 
result  
MBS item 1170034 
 
GP visit (follow-up) $38.20  0.15 for each 12 lead ECG  MBS item 2334 
Annual medication costs  
Warfarin $238.83 per year  
 
Warfarin 1mg + 3mg 
(once per day)  
PBS dispensed price for 
maximum quantity35 
Apixaban $1119.72 per year 2 tablets per day PBS dispensed price for 
maximum quantity35 
Dabigatran $1065.24 per year 2 tablets per day PBS dispensed price for 
maximum quantity35 
Rivaroxaban $1050.72 per year 1 tablet per day PBS dispensed price for 
maximum quantity35 
Annual cost of monitoring/consults for those on OAC: 
Warfarin:  $824.95 TOTAL   
• GP visits 
 
$150.35 per year 
 
3 GP visits per year (1 
initial, 2 follow up) 
MBS item 3634 = $73.95 (initial) 
MBS item 2334 = $38.20 (follow 
up) 
• Specialist consult $155.60 per year 1 visit per year  MBS item 11034 
• INR monitoring  $519 per year 30 INR tests per year MBS item 6512034, $17.30 per 
test 
NOACs: $303.15 TOTAL   
• GP visits  
 
$112.15 per year 
 
 
2 GP visits per year (1 
initial, 1 follow-up) 
 
 
MBS item 3634 = $73.95 (initial) 
MBS item 2334 = $38.20 (follow 
up) 









Item Cost/measure Details Source 
(liver function, urea, 
electrolytes, creatinine 
tests) 
$17.70 per test  
• Specialist consult $155.60 per year 1 visit per year for all 
patients on OAC 
MBS item 11034 
Other costs for those with diagnosed AF 
Echocardiogram $230.65 Once per patient  MBS item 5511334 
Stroke data 




rehabilitation and other 
ongoing medical costs 
Cadilhac et al, 200736 updated 
to 2019 prices using Australian 
Health Price Deflator Index 
QALYs per ischaemic stroke 5.09  Cadilhac et al, 201021 
Annual incidences of stroke and all-cause mortality by age and sex Martinez et al, 201437 
Bleeding costs 
Crude excess incidence rate per 
1,000 person-years of major bleeds 
for those aged 65 – 74 years 4.8 (95% CI: 2.2-7.4) 
 Martinez et al, 201437 
Crude excess incidence rate per 
1,000 person-years of major bleeds 
for those aged 75 – 84 years 4.2 (95% CI: 1.3-7.2) 
 Martinez et al 201437 
Cost of a major gastrointestinal 
bleed   $6,772 
 Australian Refined Diagnosis 
Related Groups (AR DRG)38 
Cost of a major intracranial bleed   $22,255  AR DRG38 
Proportion of major bleeds:  





AF, atrial fibrillation; iECG, smartphone electrocardiogram; OAC, oral anticoagulant; NOAC, novel oral 
anticoagulant; GP, general practitioner; ECG, electrocardiogram; PBS, pharmaceutical benefits scheme; MBS, 
medical benefits schedule; INR, international normalised ratio; QALYs, quality adjusted life years; $ = AU$, CI, 
confidence interval 
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